Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Non -Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study will evaluate DS-1062a 6.0 mg/kg vs docetaxel 75 mg/m^2 in participants with advanced or metastatic NSCLC without actionable genomic alterations and who have been previously treated with platinum-based chemotherapy and ?-PD-1/?-PD-L1 monoclonal antibody, either in combination or sequentia...
This study will evaluate DS-1062a 6.0 mg/kg vs docetaxel 75 mg/m^2 in participants with advanced or metastatic NSCLC without actionable genomic alterations and who have been previously treated with platinum-based chemotherapy and ?-PD-1/?-PD-L1 monoclonal antibody, either in combination or sequentially. The study will be divided into 3 periods: Screening Period, Treatment Period, and Follow-up Period.
Tracking Information
- NCT #
- NCT04656652
- Collaborators
- AstraZeneca
- Investigators
- Study Director: Global Clinical Leader Daiichi Sankyo, Inc.
Get Well Soon